Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | IAPP | P10997 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | APEX1 | P27695 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5194907 | 0.90 | PPARA (0.54) | PPARA | |
| SCHEMBL5675084 | 0.89 | PPARA (0.60) | PPARA | |
| SCHEMBL5681042 | 0.86 | TRPA1 (0.52) | GAA | |
| SCHEMBL4372737 | 0.81 | PTPN1 (0.40) | CNR1CNR2CYP3A4MCL1PPARA | |
| SCHEMBL16315989 | 0.79 | CNR1 (0.52) | CNR1CNR2CYP1A2CYP3A4TSHR | |
| SCHEMBL901444 | 0.79 | CYP3A4 (0.71) | GAACNR1CNR2CYP1A2CYP3A4 | |
| SCHEMBL29833121 | 0.79 | CYP3A4 (0.71) | GAACNR1CNR2CYP1A2CYP3A4 | |
| SCHEMBL238573 | 0.78 | GABRA1 (0.44) | CNR1CNR2 | |
| SCHEMBL5676633 | 0.78 | KAT8 (0.54) | CYP1A2CYP3A4PPARAIAPP | |
| SCHEMBL532205 | 0.77 | CNR1 (0.53) | GAACNR1CNR2CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019053541-A1 | ACRYLATES THROUGH OLEFIN/CARBON DIOXIDE COUPLING | SABIC GLOBAL TECHNOLOGIES B.V. (NL) | 2019-03-21 | — | — | WO | disclosed |
| WO-2019053540-A1 | METHODS OF PRODUCING ALPHA, BETA-UNSATURATED CARBOXYLIC ACID SALTS FROM ALKANES AND CARBON DIOXIDE | SABIC GLOBAL TECHNOLOGIES B.V. (NL) | 2019-03-21 | — | — | WO | disclosed |
| WO-2017158469-A1 | METHODS OF MAKING ALPHA, BETA-UNSATURATED CARBOXYLIC ACIDS OR SALTS | SABIC GLOBAL TECHNOLOGIES B.V. (NL) | 2017-09-21 | — | — | WO | disclosed |
| EP-1620447-B1 | SOLUBLE LATE TRANSITION METAL CATALYSTS FOR OLEFIN OLIGOMERIZATIONS III | EXXONMOBIL CHEM PATENTS INC (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20060036049-A1 | Soluble late transition metal catalysts for olefin oligomerizations III | ZHAO BAIYI | 2006-02-16 | — | — | US | disclosed |
| EP-1620447-A1 | SOLUBLE LATE TRANSITION METAL CATALYSTS FOR OLEFIN OLIGOMERIZATIONS III | Exxonmobil Chemical Patents Inc. (US) | 2006-02-01 | — | — | EP | disclosed |
| WO-2003102006-A1 | SOLUBLE LATE TRANSITION METAL CATALYSTS FOR OLEFIN OLIGOMERIZATIONS III | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2003-12-11 | — | — | WO | disclosed |
| US-5681669-A | ORGANIC SOLVENT CONTAINING AN AROMATIC CARBONATE AND DISSOLVED LITHIUM SALT | UBE INDUSTRIES, LTD. (JP) | 1997-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060036049-A1 | Soluble late transition metal catalysts for olefin oligomerizations III | COMT, CD69, SPR | GAA 1647/4885CNR1 3890/4885CNR2 4148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.